Results 51 to 60 of about 15,597 (227)

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention

NeuroImage, 2020
Psychedelic drugs, including the serotonin 2a (5-HT2A) receptor partial agonist psilocybin, are receiving renewed attention for their possible efficacy in treating a variety of neuropsychiatric disorders.
Frederick S. Barrett, Samuel R. Krimmel, Roland R. Griffiths, David A. Seminowicz, Brian N. Mathur   +4 more
doaj   +1 more source

Hallucinogens: mechanisms and medical complications [PDF]

, 2013
Thesis (M.A.)--Boston UniversityHallucinogens are drugs that alter consciousness by distorting primarily auditory and visual perception but they can affect any sensory system. Hallucinogens also affect judgment, orientation, memory, or emotion.
Chan, Ryan Harry Alexander
core   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Moral Neuroenhancement [PDF]

, 2017
In this chapter, we introduce the notion of “moral neuroenhancement,” offering a novel definition as well as spelling out three conditions under which we expect that such neuroenhancement would be most likely to be permissible (or ...
Douglas, Thomas, Earp, Brian D., Savulescu, Julian   +2 more
core  

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?

Neurobiology of Stress
There is growing interest in exploring the therapeutic potential and mechanisms of action of psilocybin on stress-related neuropsychiatric disorders, including depression, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD ...
Alanna Kit, Kate Conway, Savannah Makarowski, Grace O'Regan, Josh Allen, Sandy R. Shultz, Tamara S. Bodnar, Brian R. Christie   +7 more
doaj   +1 more source

Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents

Scientific Reports, 2022
Psilocybin is a hallucinogenic compound that is showing promise in the ability to treat neurological conditions such as depression and post-traumatic stress disorder.
Caroline T. Golden, Paul Chadderton
doaj   +1 more source

Psilocybin desynchronizes brain networks

, 2023
1SummaryThe relationship between the acute effects of psychedelics and their persisting neurobiological and psychological effects is poorly understood. Here, we tracked brain changes with longitudinal precision functional mapping in healthy adults before, during, and for up to 3 weeks after oral psilocybin and methylphenidate (17 MRI visits per ...
Joshua S Siegel, Subha Subramanian, Demetrius Perry, Benjamin Kay, Evan Gordon, Timothy Laumann, Rick Reneau, Caterina Gratton, Christine Horan, Nicholas Metcalf, Ravi Chacko, Julie Schweiger, Dean Wong, David Bender, Jonah Padawer-Curry, Charles Raison, Marcus Raichle, Eric J. Lenze, Abraham Z Snyder, Nico U.F. Dosenbach, Ginger Nicol   +20 more
openaire   +2 more sources

Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

Addiction, EarlyView.
Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi   +9 more
wiley   +1 more source

Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?

European Psychiatry, 2021
Introduction Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has
N. Descalço, A.B. Medeiros, C. Fernandes Santos, G. Borges   +3 more
doaj   +1 more source